RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 FXI-ASO May Represent a New Class of Antithrombotic Agents
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 10
OP 10
DO 10.1177/1559897714568644
UL http://mdc.sagepub.com/content/14/55/10.abstract
AB A single-stranded 2′-O-(2-methoxyethyl) antisense oligonucleotide to factor XI, is a promising new investigational antithrombotic agent that reduces the incidence of venous thrombosis in patients undergoing total knee replacement without increasing the incidence of bleeding episodes. The lower dose of FXI-ASO is noninferior to enoxaparin and the higher dose significantly reduces the risk of venous thromboembolism compared with enoxaparin.